Ryan K. Stansfield is a seasoned leader with over 23 years of experience in small molecule drug discovery and development. Currently serving as Director of DMPK-Toxicology at 858 Therapeutics, he has successfully led teams through critical phases of drug development, including managing IND-enabling toxicology studies and building high-performing scientific teams. Stansfield is recognized for his deep expertise in ADME, safety pharmacology, and toxicology, as well as his strategic ability to drive projects from discovery to clinical trials. Throughout his career, he has demonstrated exceptional communication skills, collaborating across functions and ensuring timely, rigorous data to support regulatory submissions. With a proven track record in managing budgets, experimental design, and in-licensing diligence, Stansfield has contributed to the successful advancement of multiple therapeutic candidates.

Michael Ekstut is a seasoned business leader with over 30 years of experience in the life sciences industry, specializing in drug discovery, development, and regulatory strategy. He has held senior leadership roles at industry-leading companies, including Certara, where he guided the company’s commercial and product strategy in the regulatory and access sector. Michael is known for his strategic vision and ability to drive innovation, optimizing clinical development programs and supporting biopharma companies in navigating complex regulatory landscapes. His deep expertise in business consulting, technology, and operational management has enabled him to successfully advise executives and investors across pharmaceuticals, biotechnology, and medical devices. Currently serving as a Senior Advisor at InSilicoTrials, Michael continues to leverage his vast experience to help organizations maximize the impact of their clinical development programs and investments.